Créer les meilleures preuves cliniques et économiques pour aider à la prise des décisions dans le cancer de la prostate


Elena Alice Dragomir

Institut de recherche du Centre universitaire de santé McGill (CUSM)


Domaine : cancer

Programme Chercheurs-boursiers - Junior 1

Concours 2016-2017

In the last 10 years, significant advances have been made in the field of prostate cancer, including new health technologies for surgery and radiation therapy for localized prostate cancer and many innovative drugs for advanced prostate cancer. These novel treatment options are generally more expensive than existing treatments.

The research program will focus on the analysis of health services utilization and drug costs vs. benefits (clinical outcomes) from diagnosis and over the metastatic castration-resistant prostate cancer period, from 2001 through 2016. Our study will show if efforts (healthcare resource utilization and associated costs) are correlated with benefits (clinical outcomes) observed over this period in the real-life setting in Quebec.

Furthermore, evidence suggests that some existing prostate cancer treatment options provide equivalent efficacy at varying costs. My research program will be focused on improving the manner in which healthcare is delivered to prostate cancer patients and finding ways to optimize health services and cost allocation. This requires accurate data on management evaluation, healthcare costs, and clinical outcomes.

In the last three years several new tests have demonstrated clinical utility and benefits in the screening, diagnosis or treatment phase of prostate cancer. Unfortunately, none of these tests are currently used routinely in clinical practice in Canada or other countries. One of the reasons is the lack of evidence regarding their cost-effectiveness.

The present research program aims to determine the best solutions for prostate cancer screening, diagnosis and treatment for improving healthcare delivery to patients with prostate cancer, while uncovering better ways to optimize health services and cost allocation. By creating evidence regarding the cost-effectiveness of interventions, we can help increase access to new advances in prostate cancer detection/diagnosis/treatment, and achieve individualized medicine.